Telix Pharmaceuticals 1H25 NPAT up 860% to $49.9m, FY25 revenue guidance of $1.18-1.23bn vs. $1.02bn consensus, R&D ...

Bell Potter has a buy rating and $27.75 price target on the ASX 200 growth share. This implies potential upside of 13% from ...

Will the market end the week on a better note? Let's find out. The post 5 things to watch on the ASX 200 on Friday appeared ...

The team at Goldman Sachs thinks BHP could be an ASX 200 dividend share to buy now.

The pope looms so large in everyday Italian life that there are lots of expressions that make light of even a dark event like ...

Microba Life Sciences (ASX:MAP), which has technology for measuring the gut microbiome, has a strategic partnership deal with ...

A sell-off in banks and miners saw the Aussie sharemarket fall for the fourth consecutive trading period on Thursday, to a ...

The sharemarket has erased over $30 billion in market value this week as the big banks took the sheen off an otherwise ...

NAB led further declines across Australia's big four lenders on Thursday following the bank's disappointing first-quarter ...

Asia-Pacific markets fell on Thursday as investors reacted to US President Donald Trump's proposal to impose 25% tariffs on auto, semiconductor, and pharmaceutical imports.

Asian shares traded mostly lower Thursday after a quiet day on Wall Street, where the S&P 500 added to its record. Worries ...

The stock was the best performer on the S&P/ASX 200 benchmark index after Megaport reported an 18% rise in annualized recurring revenue to 226.6 million Australian dollars, equivalent to about ...